March 18, 2008

Emulsions preferably of nanoparticles formed from high boiling liquid perfluorochemical substances, said particles coated with a lipid/surfactant coating are made specific to regions of activated endothelial cells by coupling said nanoparticles to a ligand specific for .alpha..sub.v.beta..sub.3 integrin, other than an antibody. The nanoparticles may further include biologically active agents, radionuclides, or other imaging agents.

14

March 18, 2008

11/305,416

December 16, 2005

424/1.29   424/1.11 424/1.37 424/1.65 424/9.3 424/9.321 534/15

A61K   51/00   (20060101)   A61M   36/14   (20060101)  

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a divisional of U.S. Ser. No. 10/351,463 filed 24 Jan. 2003 which claims benefit under 35 U.S.C. .sctn. 119(e) to provisional application No. 60/351,390 filed 24 Jan. 2002. The contents of these applications are incorporated herein by reference.

424/1.11   424/1.65   424/9.1   424/9.3   424/9.32   424/9.321   424/9.4   424/9.5   424/400   424/450   424/1.37   534/7   534/10   534/11   534/12   534/13   534/14   534/15   534/16   206/223   206/569   206/570   428/402   428/402.2  

7566442 - Integrin targeted imaging agents - Owned by Barnes-Jewish Hospital (St. Louis, MO) Bristol Myers Squibb Medical Imaging, Inc. (North Billerica, MA) Emulsions preferably of nanoparticles formed from high boiling liquid perfluorochemical substances, said particles coated with a lipid/surfactant coating are made specific to regions of activated endothelial cells by coupling said nanoparticles to a ligand specific for .alpha..sub.v.beta..sub.3 integrin, other than an antibody. The nanoparticles may further include biologically active agents, radionuclides, or other imaging agents.